A Phase 2 interventional study of Eltrombopag and hATG in Aplastic Anemia, sponsored by Novartis Pharmaceuticals. Completed at 20 sites in 6 countries. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing eltrombopag in Anemia, Aplastic — 3 open to participants now, 3 under way, 1 of them phase 3. eltrombopag · Anemia, Aplastic.
Among the 17 studies testing eltrombopag in Anemia, Aplastic, this one is the 6th largest by enrollment, is one of 2 that started in 2017, is one of 11 in phase 2, and was the 10th registered.
372 studies on the registry are indexed under Anemia, Aplastic; 99 are open to participants now.
Browse Anemia, Aplastic studies →3 of the 17 studies testing eltrombopag in Anemia, Aplastic are open now, in 2 countries. Recruiting first, the newest first:
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 3–99
Melbourne Health · Sites in Australia
Ages 18+
Assiut University
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 59 Anemia, Aplastic studies recruiting now, 21 (36%) set no upper age limit and 30 (51%) stop at 75 or younger; 38 take children under 18; 5 take healthy volunteers.
This study: 1 Year to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 14 · Phase 3 4
First in 2009; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is above the median of 37 across 281 interventional studies indexed under Anemia, Aplastic.
Median enrollment 36 across the 17 interventional studies. Of the 13 that completed or were terminated, 11 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 17 have an industry lead sponsor. The 8 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
14 studies in Anemia, Aplastic by Novartis: 1 open now, 1 under way, none of them phase 3. Of 12 finished, 7 (58%) have results posted.
Among the 14 studies in Anemia, Aplastic by Novartis, this one is one of 2 that started in 2017, is one of 7 in phase 2, and was the 7th registered.
Novartis’s Anemia, Aplastic studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing eltrombopag in Anemia, Aplastic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 14 in Anemia, Aplastic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase II, open label, multi-center, intra-patient dose escalation study to characterize the pharmacokinetics (PK) after oral administration of eltrombopag in combination with immunosuppressive therapy in pediatric patients with previously untreated or relapsed/refractory severe aplastic anemia (SAA) or recurrent aplastic anemia (AA).
All patients were treated with eltrombopag for the 26-week Treatment Period, followed by a 52-week Follow-Up Period. Patients who had been previously untreated with immunosuppressive therapy were treated according to the standard of care, hATG plus cyclosporine plus eltrombopag. Patients with relapsed/refractory SAA or recurrent AA were enrolled into one of two treatment options: hATG plus cyclosporine plus eltrombopag or cyclosporine plus eltrombopag, depending on prior treatment with immunosuppressive therapy. Patients could receive eltrombopag beyond 26 weeks if the investigator thought that the patient was still receiving clinical benefit from the drug.
After initiating treatment with eltrombopag, patients had their dose assessed and modified as tolerated, until the targeted platelet count or maximum dose was achieved. Pharmacokinetic assessments were performed at time points intended to capture steady state PK of the starting dose and highest dose achieved.
There are four separate periods of this study: Screening (signing of written informed consent through Day -1), Treatment (for 26 weeks), Follow-up (additional 52 weeks), and Long-term Follow-up (for additional 3 years). The first 3 periods were considered the Core phase of the study.
Study completion (Core) will occur when the last patient completes the 26-week treatment and 52-week Follow-up Period [at Week 78].
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Cohort A patients:
For Cohort B patients:
All patients eligible for inclusion in this study must meet all of the following criteria:
Exclusion Criteria:
Prior and/or active medical history of:
Symptomatic Paroxysmal Nocturnal Hemoglobinuria (PNH) and/or PNH clones >50% of White blood cell (WBC) or Red blood cell (RBC) at time of enrollment.
Have any of the following out-of-range laboratory values:
Pregnant or nursing (lactating) women.
Any severe and/or uncontrolled medical conditions which could cause unacceptable safety risks or compromise compliance with the protocol, such as:
Impaired cardiac function, such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
hATG (ATGAM®), CsA and eltrombopag begin on Day 1.
Drug: Eltrombopag · Drug: hATG · Drug: CsA
CsA and eltrombopag begin on Day 1.
Drug: Eltrombopag · Drug: CsA
hATG (ATGAM®), CsA and eltrombopag begin on Day 1.
Drug: Eltrombopag · Drug: hATG · Drug: CsA
Tablet for oral use, once daily or Powder for oral suspension (PfOS), once daily
Also known as: ETB115
Horse ATG (ATGAM) (hATG) is not considered an investigational medicinal product (IMP)
Cyclosporine (CsA) was supplied as either oral capsules or oral solution, administered twice a day.
Eltrombopag PK Parameters: AUCtau, AUClast
AUC tau: Area under the curve calculated to the end of the dosing interval ( tau) (mass\*time/volume) AUC last: Area under the curve calculated to the last quantifiable concentration point (Tlast) (mass\*time/volume)
Time frame: at least 11 weeks after dose initiation or later when patients are taking the highest dose, up to Week 78
Eltrombopag PK Parameter: Cmax
Cmax is the observed maximum plasma concentration following administration (mass/volume)
Time frame: at least 11 weeks after dose initiation or later when patients are taking the highest dose, up to Week 78
Eltrombopag PK Parameter: Ctrough at the Highest Dose Level
Ctrough is the pre-dose plasma concentration (mass/volume).
Time frame: at least 11 weeks after dose initiation or later when patients are taking the highest dose, up to Week 78
Percentage of Participants With an Overall Response Rate and Percentage of Participants With a Platelet Response Rate Based on Per Pediatric Committee of European Medicines Agency (PDCO)
Overall response rate (ORR) is defined as the percentage of participants who have achieved a complete response (CR) or partial response (PR) or No response (NR) by the Investigator. CR criteria: Platelet (PLT) and red blood cell (RBC) transfusion independence, Normal age-adjusted Hgb, PLT \>100 × 10\^9/L and absolute neutrophil count (ANC) \>1.5 × 10\^9/L. PR: PLT and RBC Transfusion independence and at least 2 of the following criteria: Reticulocytes \>30 × 10\^9/L, PLT \>30 × 10\^9/L, ANC \>1.5 x 10\^9L. PLT transfusion independence is defined as a period for at least 28 days without PLT transfusion. Platelet response rate (PRR): Platelet response rate is comprised of CR + PR based on the following criteria: CR: PLT \>100 × 10\^9/L; PR: PLT \>30 × 10\^9/L; NR: PLT transfusion within 4 weeks or PLT \<= 30 × 10\^9/L.
Time frame: Week 12, Week 26, Week 52, Week 78
Hematologic Counts (Platelets (Blood), Neutrophils (Blood))
Individual Platelets (PLT) and neutrophil counts were summarized for all participants.
Time frame: Week 12, Week 26, Week 52, Week 78, Week 130, Week 182, Week 234
Hematologic Counts (Hemoglobin (Blood))
Individual hemoglobin (Hgb) counts were summarized for all participants.
Time frame: Week 12, Week 26, Week 52, Week 78, Week 130, Week 182, Week 234
Number of Red Blood Cells (RBC) Transfusions
Number of transfusions during the treatment period refers to total number of RBC transfusions participants have received while on treatment.
Time frame: From date of first dose to approx. 4.5 years
Frequency of Red Blood Cell (RBC) Transfusions
Frequency of transfusions during the treatment period refers to number of RBC transfusions during the treatment period divided by number of months of treatment duration.
Time frame: From date of first dose to approx. 4.5 years
Number of Platelet (PLT) Transfusions
Number of transfusions during the treatment period refers to total number of PLT transfusions participants have received while on treatment.
Time frame: From date of first dose to approx. 4.5 years
Frequency of Platelet (PLT) Transfusions
Frequency of transfusions during the treatment period refers to number of PLT transfusions during the treatment period divided by number of months of treatment duration.
Time frame: From date of first dose to approx. 4.5 years
Total Duration of Red Blood Cell (RBC) Transfusion Independence During the Treatment Period
RBC transfusion independence is defined as a period of time of at least 56 days without RBC transfusion. Duration of RBC transfusion independence is defined as a period of time of at least 56 days without RBC transfusion. First transfusion duration was calculated as the date of the day before the first transfusion after baseline minus the date of first exposure eltrombopag + 1.
Time frame: From date of first dose to approx. 4.5 years
Total Duration of Platelet (PLT) Transfusion Independence During the Treatment Period
Platelet transfusion independence during the treatment period is defined as the duration from the first day of the 28-day period without PLT transfusion until the occurrence of a PLT transfusion after the period free from any PLT transfusion. Duration of PLT transfusion independence is defined as a period of time of at least 28 days without platelet transfusion. First transfusion duration was calculated as the date of the day before the first transfusion after baseline minus the date of first exposure eltrombopag + 1.
Time frame: From date of first dose to approx. 4.5 years
Maximum Duration of Red Blood Cell (RBC) Transfusion Independence
RBC transfusion independence is defined as a period of time of at least 56 days without RBC transfusion. Maximum duration of RBC transfusion independence is defined as the maximum duration among the durations of RBC transfusion independence. First transfusion duration was calculated as the date of first transfusion after baseline minus the date of first exposure eltrombopag + 1.
Time frame: From date of first dose to approx. 4.5 years
Maximum Duration of Platelet (PLT) Transfusion Independence
Maximum duration of PLT transfusion independence is defined as the maximum duration among the durations of PLT transfusion independence. First transfusion duration was calculated as the date of first transfusion after baseline minus the date of first exposure eltrombopag + 1.
Time frame: From date of first dose to approx. 4.5 years
Overall Bone Marrow Cellularity
Percentage of cells in bone marrow biopsy - a comprehensive diagnostic evaluation to distinguish between the various bone marrow disorders.
Time frame: Screening, Week 26, Week 52, Week 78, Week 130, Week 182, Week 234
Bone Marrow Morphology
Percentage of morphology (erythropoiesis, granulopoiesis, megakaryopoiesis, CD34+ (blast cells) cells in bone marrow aspirate - a comprehensive diagnostic evaluation to distinguish between the various bone marrow disorders.
Time frame: Screening, Week, 26, Week 52, Week 78, Week 130, Week 182, Week 234
Bone Marrow Cytogenetics
Number of bone marrow cytogenetics (chromosomal structure) by kryotyping and Fluorescence in situ hybridization (FISH). This is a comprehensive diagnostic evaluation to distinguish between the various bone marrow disorders.
Time frame: Screening, Week 12, Week 26, Week 52, Week 78, Week 130, Week 182, Week 234
Acceptability and Palatability for Both Tablets and Powder Formulation for Oral Solution (PfOS)
Standardized (total) summary score, ranged from 0-100, (where 0 means worst and 100 means the best), was derived from all items from the questionnaire based on a scoring matrix. The questionnaire was completed by parents and caregivers of patients under 12 years of age (ObsRO) and a questionnaire completed by patients 12 years and older (PRO).
Time frame: any day from Day 1 of drug initiation up to Week 78
Clonal Evolution to Paroxysmal Nocturnal Hemoglobinuria (PNH)
Percentage of participants with clonal evolution to Paroxysmal Nocturnal Hemoglobinuria (PNH).
Time frame: Baseline, Week (W) 26 Day (D) 1, W52D1, W78D1, W130D1, W182D1, W234D1
Exposure (AUCtau) - Response Relationship of Eltrombopag and Best Overall Response Rate by Age Groups
Pharmacokinetic parameter (AUCtau) of eltrombopag at the highest dose in relationship to best overall response rate in regard to complete response (CR), partial response (PR) and no response (NR). AUC tau: Area under the curve calculated to the end of the dosing interval (tau) (mass\*time/volume)
Time frame: at least 11 weeks after dose initiation or later when patients are taking the highest dose, up to Week 78
Exposure (Cmax, Ctrough) - Response Relationship of Eltrombopag and Best Overall Response Rate by Age Groups
Pharmacokinetic parameters (Cmax and Ctrough) of eltrombopag at the highest dose in relationship to overall response rate in regard to complete response (CR), partial response (PR) and no response (NR). Cmax is the observed maximum plasma concentration following administration (mass/volume). Ctrough is the pre-dose plasma concentration (mass/volume).
Time frame: at least 11 weeks after dose initiation or later when patients are taking the highest dose, up to Week 78
Exposure (AUCtau) - Response Relationship of Eltrombopag and Best Platelet Response Rate by Age Groups
Pharmacokinetic parameter (AUCtau) of eltrombopag at the highest dose in relationship to platelet response rate. AUC tau: Area under the curve calculated to the end of the dosing interval ( tau) (mass\*time/volume)
Time frame: at least 11 weeks after dose initiation or later when patients are taking the highest dose, up to Week 78
Exposure (Cmax, Ctrough) - Response Relationship of Eltrombopag and Best Platelet Response Rate by Age Groups
Pharmacokinetic parameters (Cmax and Ctrough) of eltrombopag at the highest dose in relationship to platelet response rate. Cmax is the observed maximum plasma concentration following administration (mass/volume). Ctrough is the pre-dose plasma concentration (mass/volume).
Time frame: at least 11 weeks after dose initiation or later when patients are taking the highest dose, up to Week 78
Alternate Overall Response Rate (aORR)
Alternate overall responses were derived using hematological parameters (i.e., hemoglobin, platelet, reticulocyte, and ANC). aORR is defined as the percentage of participants who achieved an alternate complete response (aCR) or an alternate partial response (aPR)
Time frame: Week 12, Week 26, Week 52, Week 78
Pharmacokinetics (PK) of Eltrombopag at the Starting Dose (AUCtau)
PK parameter, AUCtau. AUC tau: Area under the curve calculated to the end of the dosing interval (tau) (mass\*time/volume)
Time frame: Week 3 Day 1
PK of Eltrombopag at the Starting Dose (Cmax)
PK parameter, Cmax Cmax is the observed maximum plasma concentration following administration (mass/volume)
Time frame: Week 3 Day 1
PK of Eltrombopag at the Starting Dose (Ctrough)
PK parameter, Ctrough Ctrough is the pre-dose plasma concentration (mass/volume).
Time frame: Week 3 Day 1
Study was conducted in 19 sites in 6 countries
| Milestone | Cohort A: Regimen 1 | Cohort A: Regimen 2 | Cohort B |
|---|---|---|---|
| Started | 10 | 4 | 37 |
| Participants who entered 26-week treatment phase | 10 | 4 | 37 |
| Completed 26-week (wk) treatment | 7 | 4 | 25 |
| Entered 52-wk post-treatment follow up phase 1 (wk 78) | 9 | 4 | 26 |
| Did not enter 52-wk post-treatment f/u phase (wk 78) | 1 | 0 | 11 |
| Entered 3-year post-treatment follow-up 2 | 6 | 3 | 19 |
| Did not complete ptfu2 | 1 | 1 | 9 |
| Completed | 5 | 2 | 10 |
| Not completed | 5 | 2 | 27 |
| Withdrew: Adverse event | 0 | 0 | 2 |
| Withdrew: Physician decision | 3 | 0 | 8 |
| Withdrew: Progressive disease | 0 | 0 | 3 |
| Withdrew: Participant/guardian decision | 2 | 1 | 11 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Completed study treatment/discontinued study for unspecified reasons | 0 | 0 | 2 |
AUC tau: Area under the curve calculated to the end of the dosing interval ( tau) (mass\*time/volume) AUC last: Area under the curve calculated to the last quantifiable concentration point (Tlast) (mass\*time/volume)
| hr*ng/mL | Cohort A: Regimen 1 (1 to <6 Years) | Cohort A: Regimen 1 (6 to <18 Years) | Cohort A: Regimen 2 (6 to <18 Years) | Cohort B (1 to < 6 Years) | Cohort B (6 to <18 Years) |
|---|---|---|---|---|---|
| AUCtau | 272000 | 285000 ± 72.4 | 406000 | 502000 ± 65.6 | 275000 ± 52.6 |
| AUClast | 272000 | 300000 ± 60.2 | 166000 ± 196 | 477000 ± 52.5 | 259000 ± 75.1 |
Cmax is the observed maximum plasma concentration following administration (mass/volume)
| ng/mL | Cohort A: Regimen 1 ( 1 to <6 Years) | Cohort A: Regimen 1 (6 to <18 Years) | Cohort A: Regimen 2 (6 to <18 Years) | Cohort B (1 to < 6 Years) | Cohort B (6 to <18 Years) |
|---|---|---|---|---|---|
| Eltrombopag PK Parameter: Cmax | 16100 | 14500 ± 66.7 | 14300 ± 56.7 | 27100 ± 40.6 | 15600 ± 47.2 |
Ctrough is the pre-dose plasma concentration (mass/volume).
| ng/mL | Cohort A: Regimen 1 (1 to <6 Years) | Cohort A: Regimen 1 (6 to <18 Years) | Cohort A: Regimen 2 (6 to <18 Years) | Cohort B (1 to < 6 Years) | Cohort B (6 to <18 Years) |
|---|---|---|---|---|---|
| Eltrombopag PK Parameter: Ctrough at the Highest Dose Level | 5470 | 9930 ± 68.7 | 9900 ± 32.3 | 13400 ± 113 | 9670 ± 64.5 |
Overall response rate (ORR) is defined as the percentage of participants who have achieved a complete response (CR) or partial response (PR) or No response (NR) by the Investigator. CR criteria: Platelet (PLT) and red blood cell (RBC) transfusion independence, Normal age-adjusted Hgb, PLT \>100 × 10\^9/L and absolute neutrophil count (ANC) \>1.5 × 10\^9/L. PR: PLT and RBC Transfusion independence and at least 2 of the following criteria: Reticulocytes \>30 × 10\^9/L, PLT \>30 × 10\^9/L, ANC \>1.5 x 10\^9L. PLT transfusion independence is defined as a period for at least 28 days without PLT transfusion. Platelet response rate (PRR): Platelet response rate is comprised of CR + PR based on the following criteria: CR: PLT \>100 × 10\^9/L; PR: PLT \>30 × 10\^9/L; NR: PLT transfusion within 4 weeks or PLT \<= 30 × 10\^9/L.
| Percentage of participants | Cohort A: Regimen 1 | Cohort A: Regimen 2 | Cohort B |
|---|---|---|---|
| ORR: Week 12 | 30.0 (6.7 to 65.2) | 50.0 (6.8 to 93.2) | 13.5 (4.5 to 28.8) |
| ORR: Week 26 | 70.0 (34.8 to 93.3) | 75.0 (19.4 to 99.4) | 45.9 (29.5 to 63.1) |
| ORR: Week 52 | 50.0 (18.7 to 81.3) | 50.0 (6.8 to 93.2) | 43.2 (27.1 to 60.5) |
| ORR: Week 78 | 50.0 (18.7 to 81.3) | 75.0 (19.4 to 99.4) | 40.5 (24.8 to 57.9) |
| PRR: Week 12 | 50.0 (18.7 to 81.3) | 75.0 (19.4 to 99.4) | 43.2 (27.1 to 60.5) |
| PRR: Week 26 | 60.0 (26.2 to 87.8) | 75.0 (19.4 to 99.4) | 54.1 (36.9 to 70.5) |
| PRR: Week 52 | 50.0 (18.7 to 81.3) | 75.0 (19.4 to 99.4) | 48.6 (31.9 to 65.6) |
| PRR: Week 78 | 50.0 (18.7 to 81.3) | 75.0 (19.4 to 99.4) | 45.9 (29.5 to 63.1) |
Individual Platelets (PLT) and neutrophil counts were summarized for all participants.
| x 10^9 cells/L | Cohort A: Regimen 1 | Cohort A: Regimen 2 | Cohort B |
|---|---|---|---|
| Week 12: Platelets (blood) | 40.500 (5.00 to 260.00) | 73.500 (17.00 to 172.00) | 50.000 (3.00 to 338.00) |
| Week 26: Platelets (blood) | 60.500 (3.00 to 222.00) | 122.500 (49.00 to 182.00) | 106.000 (3.00 to 230.00) |
| Week 52: Platelets (blood) | 147.000 (7.00 to 164.00) | 160.500 (22.00 to 240.00) | 163.000 (28.00 to 318.00) |
| Week 78: Platelets (blood) | 133.500 (6.00 to 308.00) | 140.000 (88.00 to 273.00) | 152.500 (28.00 to 278.00) |
| Week 130: Platelets (blood) | 155.000 (43.00 to 195.00) | 138.500 (128.00 to 149.00) | 139.000 (31.00 to 245.00) |
| Week 182: Platelets (blood) | 173.000 (9.00 to 221.00) | 149.000 (127.00 to 171.00) | 182.000 (104.00 to 223.00) |
| Week 234: Platelets (blood) | 176.000 (110.00 to 196.00) | 129.000 (129.00 to 129.00) | 189.000 (147.00 to 264.00) |
| Week 12: Neutrophils (blood) | 1.795 (0.72 to 11.72) | 1.555 (1.01 to 4.15) | 1.100 (0.00 to 8.10) |
| Week 26: Neutrophils (blood) | 2.495 (0.52 to 4.60) | 1.258 (0.78 to 1.63) | 1.640 (0.40 to 4.47) |
| Week 52: Neutrophils (blood) | 3.110 (0.17 to 4.29) | 1.721 (1.11 to 3.47) | 2.600 (0.83 to 5.75) |
| Week 78: Neutrophils (blood) | 3.617 (1.02 to 4.91) | 1.234 (0.56 to 1.34) | 2.292 (0.69 to 5.41) |
| Week 130: Neutrophils (blood) | 2.732 (1.04 to 6.72) | 0.892 (0.57 to 1.21) | 1.690 (1.30 to 2.67) |
| Week 182: Neutrophils (blood) | 3.014 (1.00 to 6.09) | 1.471 (0.61 to 2.33) | 3.100 (2.07 to 4.30) |
| Week 234: Neutrophils (blood) | 2.630 (2.04 to 4.40) | 1.200 (1.20 to 1.20) | 2.078 (1.02 to 4.70) |
Individual hemoglobin (Hgb) counts were summarized for all participants.
| g/L | Cohort A: Regimen 1 | Cohort A: Regimen 2 | Cohort B |
|---|---|---|---|
| Week 12 | 89.5 (64 to 131) | 87.0 (81 to 94) | 88.0 (57 to 130) |
| Week 26 | 101.0 (59 to 128) | 98.5 (93 to 102) | 95.0 (44 to 125) |
| Week 52 | 116.0 (52 to 138) | 104.5 (95 to 117) | 110.0 (92 to 133) |
| Week 78 | 118.5 (67 to 138) | 92.0 (89 to 119) | 117.0 (97 to 148) |
| Week 130 | 119.5 (88 to 141) | 125.5 (122 to 129) | 126.0 (109 to 142) |
| Week 182 | 126.0 (96 to 138) | 125.5 (115 to 136) | 127.0 (66 to 129) |
| Week 234 | 126.0 (116 to 147) | 128.0 (128 to 128) | 125.0 (110 to 144) |
Number of transfusions during the treatment period refers to total number of RBC transfusions participants have received while on treatment.
| RBC transfusions | Cohort A: Regimen 1 | Cohort A: Regimen 2 | Cohort B |
|---|---|---|---|
| approx. 3 years | 7.0 (1 to 17) | 3.0 (1 to 34) | 7.0 (1 to 26) |
| approx. 4.5 years | 7.0 (1 to 17) | 3.0 (1 to 34) | 7.0 (1 to 26) |
Frequency of transfusions during the treatment period refers to number of RBC transfusions during the treatment period divided by number of months of treatment duration.
| RBC transfusions per month | Cohort A: Regimen 1 | Cohort A: Regimen 2 | Cohort B |
|---|---|---|---|
| approx. 3 years (n = 8, 3, 33) | 1.5 (0 to 4) | 0.2 (0 to 3) | 0.9 (0 to 5) |
| approx. 4.5 years (n = 8, 3, 33) | 1.5 (0 to 4) | 0.2 (0 to 3) | 0.9 (0 to 5) |
Number of transfusions during the treatment period refers to total number of PLT transfusions participants have received while on treatment.
| Platelet transfusions | Cohort A: Regimen 1 | Cohort A: Regimen 2 | Cohort B |
|---|---|---|---|
| approx. 3 years | 13.0 (3 to 48) | 53.0 (53 to 53) | 13.0 (2 to 65) |
| approx. 4.5 years | 13.0 (3 to 48) | 53.0 (53 to 53) | 13.0 (2 to 65) |
Frequency of transfusions during the treatment period refers to number of PLT transfusions during the treatment period divided by number of months of treatment duration.
| Platelet transfusions per month | Cohort A: Regimen 1 | Cohort A: Regimen 2 | Cohort B |
|---|---|---|---|
| approx. 3 years | 2.0 (0 to 14) | 4.2 (4.2 to 4.2) | 2.0 (0 to 13) |
| approx. 4.5 years | 2.0 (0 to 14) | 4.2 (4.2 to 4.2) | 2.0 (0 to 13) |
RBC transfusion independence is defined as a period of time of at least 56 days without RBC transfusion. Duration of RBC transfusion independence is defined as a period of time of at least 56 days without RBC transfusion. First transfusion duration was calculated as the date of the day before the first transfusion after baseline minus the date of first exposure eltrombopag + 1.
| days | Cohort A: Regimen 1 | Cohort A: Regimen 2 | Cohort B |
|---|---|---|---|
| approx. 3 years | 355.0 (185 to 860) | 430.0 (262 to 558) | 267.0 (58 to 1074) |
| approx. 4.5 years | 355.0 (185 to 1637) | 430.0 (262 to 558) | 267.0 (58 to 1296) |
Platelet transfusion independence during the treatment period is defined as the duration from the first day of the 28-day period without PLT transfusion until the occurrence of a PLT transfusion after the period free from any PLT transfusion. Duration of PLT transfusion independence is defined as a period of time of at least 28 days without platelet transfusion. First transfusion duration was calculated as the date of the day before the first transfusion after baseline minus the date of first exposure eltrombopag + 1.
| days | Cohort A: Regimen 1 | Cohort A: Regimen 2 | Cohort B |
|---|---|---|---|
| approx. 3 years | 252.0 (36 to 860) | 360.5 (139 to 560) | 268.0 (34 to 1100) |
| approx. 4.5 years | 252.0 (36 to 1637) | 360.5 (139 to 560) | 268.0 (34 to 1322) |
RBC transfusion independence is defined as a period of time of at least 56 days without RBC transfusion. Maximum duration of RBC transfusion independence is defined as the maximum duration among the durations of RBC transfusion independence. First transfusion duration was calculated as the date of first transfusion after baseline minus the date of first exposure eltrombopag + 1.
| days | Cohort A: Regimen 1 | Cohort A: Regimen 2 | Cohort B |
|---|---|---|---|
| approx. 3 years | 355.0 (185 to 860) | 321.0 (262 to 430) | 259.0 (58 to 1074) |
| approx. 4.5 years | 355.0 (185 to 1637) | 321.0 (262 to 430) | 262.0 (58 to 1296) |
Maximum duration of PLT transfusion independence is defined as the maximum duration among the durations of PLT transfusion independence. First transfusion duration was calculated as the date of first transfusion after baseline minus the date of first exposure eltrombopag + 1.
| days | Cohort A: Regimen 1 | Cohort A: Regimen 2 | Cohort B |
|---|---|---|---|
| approx. 3 years | 252.0 (36 to 860) | 360.5 (64 to 560) | 249.5 (34 to 1067) |
| approx. 4.5 years | 252.0 (36 to 1637) | 360.5 (64 to 560) | 249.5 (34 to 1289) |
Percentage of cells in bone marrow biopsy - a comprehensive diagnostic evaluation to distinguish between the various bone marrow disorders.
| Percentage of cells | Cohort A: Regimen 1 | Cohort A: Regimen 2 | Cohort B |
|---|---|---|---|
| Overall cellularity (OC): Screening | 11.5 (5.0 to 30.0) | 32.5 (20.0 to 50.0) | 4.0 (2.0 to 40.0) |
| OC: Week 26 | 30.0 (10.0 to 50.0) | 30.0 (20.0 to 50.0) | 22.5 (2.0 to 55.0) |
| OC: Week 52 | 35.0 (5.0 to 45.0) | 50.0 (50.0 to 65.0) | 35.0 (3.0 to 55.0) |
| OC: Week 78 | 32.5 (5.0 to 50.0) | 50.0 (50.0 to 50.0) | 35.0 (3.0 to 70.0) |
| OC: Week 130 | 45.0 (40.0 to 50.0) | 45.0 (45.0 to 45.0) | 40.0 (10.0 to 60.0) |
| OC: Week 182 | — | — | 52.5 (45.0 to 60.0) |
| OC: Week 234 | 52.5 (30.0 to 55.0) | — | 47.5 (25.0 to 60.0) |
| Hematologic cellularity (HC): Screening | 5.0 (1.0 to 25.0) | 22.5 (10.0 to 45.0) | 1.5 (1.0 to 25.0) |
| HC: Week 26 | 21.0 (5.0 to 45.0) | 25.0 (15.0 to 40.0) | 17.5 (1.0 to 50.0) |
| HC: Week 52 | 30.0 (30.0 to 40.0) | 45.0 (45.0 to 45.0) | 27.5 (2.0 to 50.0) |
| HC: Week 78 | 25.0 (3.0 to 40.0) | 40.0 (40.0 to 40.0) | 30.0 (2.0 to 50.0) |
| HC: Week 130 | 35.0 (30.0 to 40.0) | 35.0 (35.0 to 35.0) | 35.0 (8.0 to 50.0) |
| HC: Week 182 | — | — | 60.0 (40.0 to 80.0) |
| HC: Week 234 | 45.0 (25.0 to 50.0) | — | 37.5 (20.0 to 50.0) |
Percentage of morphology (erythropoiesis, granulopoiesis, megakaryopoiesis, CD34+ (blast cells) cells in bone marrow aspirate - a comprehensive diagnostic evaluation to distinguish between the various bone marrow disorders.
| Percentage of cells | Cohort A: Regimens 1 | Cohort A: Regimen 2 | Cohort B |
|---|---|---|---|
| Erythroid cells: Screening | 11.5 (0.0 to 28.0) | 27.0 (19.0 to 39.0) | 5.0 (0.0 to 38.0) |
| Erythroid cells: Week 26 | 10.0 (1.0 to 25.0) | 12.0 (2.0 to 22.0) | 18.0 (0.0 to 55.0) |
| Erythroid cells: Week 52 | 13.0 (4.0 to 37.0) | 12.0 (2.0 to 17.0) | 14.5 (1.0 to 28.0) |
| Erythroid cells: Week 78 | 14.0 (5.0 to 20.0) | 15.0 (15.0 to 15.0) | 20.5 (4.0 to 26.0) |
| Erythroid cells: Week 130 | 22.0 (22.0 to 22.0) | 15.0 (15.0 to 15.0) | 17.0 (5.0 to 32.0) |
| Erythroid cells: Week 184 | — | — | 11.0 (7.0 to 15.0) |
| Erythroid cells: Week 234 | 13.0 (5.0 to 20.0) | — | 18.0 (13.0 to 33.0) |
| Neutrophil: Screening | 33.0 (1.0 to 48.0) | 29.5 (19.0 to 48.0) | 8.0 (0.0 to 45.0) |
| Neutrophil cells: Week 26 | 52.0 (34.0 to 63.0) | 47.0 (29.0 to 66.0) | 50.0 (17.0 to 78.0) |
| Neutrophil: Week 52 | 48.5 (32.0 to 59.0) | 62.0 (57.0 to 67.0) | 52.5 (20.0 to 76.0) |
| Neutrophil: Week 78 | 43.0 (4.0 to 54.0) | 53.0 (53.0 to 53.0) | 52.0 (34.0 to 67.0) |
| Neutrophil cells: Week 130 | 44.0 (44.0 to 44.0) | 51.0 (51.0 to 51.0) | 53.0 (39.0 to 65.0) |
| Neutrophil cells: Week 182 | — | — | 31.0 (5.0 to 57.0) |
| Neutrophil cells: Week 234 | 43.5 (30.0 to 56.0) | — | 33.5 (25.0 to 36.0) |
| Blast cells: Screening | 0.00 (0.0 to 1.0) | 1.0 (0.0 to 5.0) | 0.0 (0.0 to 3.0) |
| Blast cells: Week 26 | 0.0 (0.0 to 2.0) | 1.0 (0.0 to 2.0) | 0.0 (0.0 to 1.0) |
| Blast cells: Week 52 | 0.0 (0.0 to 1.0) | 1.0 (0.0 to 2.0) | 0.0 (0.0 to 1.0) |
| Blast cells: Week 78 | 0.0 (0.0 to 1.0) | 0.0 (0.0 to 0.0) | 1.0 (0.0 to 2.0) |
| Blast cells: Week 130 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) | 1.0 (0.0 to 2.0) |
| Blast cells: Week 182 | — | — | 13.0 (0.0 to 26.0) |
| Blast cells: Week 234 | 0.0 (0.0 to 2.0) | — | 1.0 (0.0 to 2.0) |
Number of bone marrow cytogenetics (chromosomal structure) by kryotyping and Fluorescence in situ hybridization (FISH). This is a comprehensive diagnostic evaluation to distinguish between the various bone marrow disorders.
| Participants | Cohort A: Regimen 1 | Cohort A: Regimen 2 | Cohort B |
|---|---|---|---|
| FISH Chr 7 @ Screening — Normal | 10 | 4 | 26 |
| FISH Chr 7 @ Screening — Abnormal | 0 | 0 | 0 |
| FISH Chr 7 @ Screening — Not Available | 0 | 0 | 2 |
| FISH Chr 7 @ Week 12 — Normal | 9 | 2 | 26 |
| FISH Chr 7 @ Week 12 — Abnormal | 0 | 0 | 0 |
| FISH Chr 7 @ Week 12 — Not Available | 0 | 0 | 1 |
| FISH Chr 7 @ Week 26 — Normal | 8 | 3 | 28 |
| FISH Chr 7 @ Week 26 — Abnormal | 0 | 0 | 0 |
| FISH Chr 7 @ Week 26 — Not Available | 1 | 0 | 1 |
| FISH Chr 7 @ Week 52 — Normal | 6 | 3 | 15 |
| FISH Chr 7 @ Week 52 — Abnormal | 0 | 0 | 0 |
| FISH Chr 7 @ Week 52 — Not Available | 0 | 0 | 1 |
| FISH Chr 7 @ Week 78 — Normal | 6 | 1 | 13 |
| FISH Chr 7 @ Week 78 — Abnormal | 0 | 0 | 0 |
| FISH Chr 7 @ Week 78 — Not Available | 0 | 0 | 2 |
| FISH Chr 7 @ Week 130 — Normal | 2 | 1 | 9 |
| FISH Chr 7 @ Week 130 — Abnormal | 0 | 0 | 0 |
| FISH Chr 7 @ Week 130 — Not Available | 1 | 0 | 1 |
| FISH Chr 7 @ Week 182 — Normal | 3 | 1 | 8 |
| FISH Chr 7 @ Week 182 — Abnormal | 0 | 0 | 0 |
| FISH Chr 7 @ Week 182 — Not Available | 0 | 0 | 0 |
| FISH Chr 7 @ Week 234 — Normal | 4 | 0 | 4 |
| FISH Chr 7 @ Week 234 — Abnormal | 0 | 0 | 0 |
| FISH Chr 7 @ Week 234 — Not Available | 0 | 0 | 0 |
| Karyotype @ Screening — Normal | 8 | 4 | 19 |
| Karyotype @ Screening — Abnormal | 0 | 0 | 0 |
| Karyotype @ Screening — Not Available | 2 | 0 | 8 |
| Karyotype @ Week 12 — Normal | 8 | 2 | 25 |
| Karyotype @ Week 12 — Abnormal | 1 | 0 | 0 |
| Karyotype @ Week 12 — Not Available | 0 | 0 | 6 |
| Karyotype @ Week 26 — Normal | 7 | 3 | 25 |
| Karyotype @ Week 26 — Abnormal | 1 | 0 | 1 |
| Karyotype @ Week 26 — Not Available | 1 | 0 | 5 |
| Karyotype @ Week 52 — Normal | 5 | 3 | 15 |
| Karyotype @ Week 52 — Abnormal | 0 | 0 | 0 |
| Karyotype @ Week 52 — Not Available | 0 | 0 | 2 |
| Karyotype @ Week 78 — Normal | 4 | 1 | 13 |
| Karyotype @ Week 78 — Abnormal | 1 | 0 | 0 |
| Karyotype @ Week 78 — Not Available | 1 | 0 | 2 |
| Karyotype @ Week 130 — Normal | 2 | 1 | 8 |
| Karyotype @ Week 130 — Abnormal | 0 | 0 | 0 |
| Karyotype @ Week 130 — Not Available | 2 | 0 | 2 |
| Karyotype @ Week 182 — Normal | 3 | 1 | 7 |
| Karyotype @ Week 182 — Abnormal | 0 | 0 | 1 |
| Karyotype @ Week 182 — Not Available | 0 | 0 | 0 |
| Karyotype @ Week 234 — Normal | 4 | 0 | 4 |
| Karyotype @ Week 234 — Abnormal | 0 | 0 | 0 |
| Karyotype @ Week 234 — Not Available | 0 | 0 | 0 |
Standardized (total) summary score, ranged from 0-100, (where 0 means worst and 100 means the best), was derived from all items from the questionnaire based on a scoring matrix. The questionnaire was completed by parents and caregivers of patients under 12 years of age (ObsRO) and a questionnaire completed by patients 12 years and older (PRO).
| scores on a scale (of acceptability) | Cohort A: Regimen 1 | Cohort A: Regimen 2 | Cohort B |
|---|---|---|---|
| Acceptability (including palatability) - Tablet | 71.0 (58.0 to 96.0) | 75.0 (58.0 to 88.0) | 71.0 (46.0 to 96.0) |
| Acceptability (including palatability) - PfOS | — | — | 71.0 (32.0 to 82.0) |
Percentage of participants with clonal evolution to Paroxysmal Nocturnal Hemoglobinuria (PNH).
| Percentage of participants | Cohort A: Regimen 1 | Cohort A: Regimen 2 | Cohort B |
|---|---|---|---|
| Baseline: Positive clonal evolution | 20.0 | 25.0 | 29.7 |
| Baseline: Negative clonal evolution | 80.0 | 75.0 | 64.9 |
| Baseline: Missing | 0.0 | 0.0 | 5.4 |
| W26D1: Positive clonal evolution | 10.0 | 50.0 | 8.1 |
| W26D1: Negative clonal evolution | 80.0 | 25.0 | 64.9 |
| W26D1: Missing | 10.0 | 25.0 | 27.0 |
| W52D1: Positive clonal evolution | 0 | 25.0 | 2.7 |
| W52D1: Negative clonal evolution | 30.0 | 25.0 | 29.7 |
| W52D1: Missing | 70.0 | 50.0 | 67.6 |
| W78D1: Positive clonal evolution | 0 | 25.0 | 0 |
| W78D1: Negative clonal evolution | 40.0 | 25.0 | 21.6 |
| W78D1: Missing | 60.0 | 50.0 | 78.4 |
| W130D1: Positive clonal evolution | 0 | 0 | 0 |
| W130D1: Negative clonal evolution | 30.0 | 0 | 8.1 |
| W130D1: Missing | 70.0 | 100.0 | 91.9 |
| W182D1: Positive clonal evolution | 10.0 | 0 | 2.7 |
| W182D1: Negative clonal evolution | 20.0 | 0 | 8.1 |
| W182D1: Missing | 70.0 | 100.0 | 89.2 |
| W234D1: Positive clonal evolution | 0 | 0 | 2.7 |
| W234D1: Negative clonal evolution | 30.0 | 0 | 2.7 |
| W234D1: Missing | 70.0 | 100.0 | 94.6 |
Pharmacokinetic parameter (AUCtau) of eltrombopag at the highest dose in relationship to best overall response rate in regard to complete response (CR), partial response (PR) and no response (NR). AUC tau: Area under the curve calculated to the end of the dosing interval (tau) (mass\*time/volume)
| hr*ng/mL | Cohort A: Regimen 1 (1 to <6 Years) | Cohort A: Regimen 1 (6 to <18 Years) | Cohort A: Regimen 2 (6 to <18 Years) | Cohort B (1 to <6 Years) | Cohort B (6 to <18 Years) |
|---|---|---|---|---|---|
| No response (NR) | 816000 | 390000 | — | 1260000 ± 27.0 | — |
| Complete response (CR) | — | 769000 ± 87.3 | — | 2260000 | 503000 ± 57.4 |
| Partial response (PR) | — | — | 1220000 | 671000 | 963000 ± 80.6 |
Pharmacokinetic parameters (Cmax and Ctrough) of eltrombopag at the highest dose in relationship to overall response rate in regard to complete response (CR), partial response (PR) and no response (NR). Cmax is the observed maximum plasma concentration following administration (mass/volume). Ctrough is the pre-dose plasma concentration (mass/volume).
| ng/mL | Cohort A: Regimen 1 (1 to <6 Years) | Cohort A: Regimen 1 (6 to <18 Years) | Cohort A: Regimen 2 (6 to <18 Years) | Cohort B (1 to <6 Years) | Cohort B (6 to <18 Years) |
|---|---|---|---|---|---|
| Cmax: No Response | 48400 ± 0 | 33900 ± 115 | — | 84900 ± 32.6 | 39200 ± 33.1 |
| Cmax: Complete Response | — | 35700 ± 88.3 | — | 112000 | 31200 ± 63.7 |
| Cmax: Partial Response | — | — | 24800 ± 212 | 60500 ± 26.6 | 54000 ± 54.4 |
| Ctrough: No Response | 16400 | 19900 ± 106 | — | 37800 ± 32.6 | 18500 ± 43.6 |
| Ctrough: Complete Response | — | 27000 ± 104 | — | 84700 | 20100 ± 72.8 |
| Ctrough: Partial Response | — | — | 17100 ± 151 | 23800 ± 194 | 35300 ± 65.9 |
Pharmacokinetic parameter (AUCtau) of eltrombopag at the highest dose in relationship to platelet response rate. AUC tau: Area under the curve calculated to the end of the dosing interval ( tau) (mass\*time/volume)
| hr*ng/mL | Cohort A: Regimen 1 (1 to <6 Years) | Cohort A: Regimen 1 (6 to <18 Years) | Cohort A: Regimen 2 (6 to <18 Years) | Cohort B (1 to <6 Years) | Cohort B (6 to <18 Years) |
|---|---|---|---|---|---|
| No Response | 816000 | — | — | — | 1280000 |
| Complete Response | — | 769000 ± 87.3 | 1220000 | 1670000 ± 45.2 | 563000 ± 67.3 |
| Partial Response | — | 390000 | — | 1090000 ± 43.5 | — |
Pharmacokinetic parameters (Cmax and Ctrough) of eltrombopag at the highest dose in relationship to platelet response rate. Cmax is the observed maximum plasma concentration following administration (mass/volume). Ctrough is the pre-dose plasma concentration (mass/volume).
| ng/mL | Cohort A: Regimen 1 (1 to <6 Years) | Cohort A: Regimen 1 (6 to <18 Years) | Cohort A: Regimen 2 (6 to <18 Years) | Cohort B (1 to <6 Years) | Cohort B (6 to <18 Years) |
|---|---|---|---|---|---|
| Cmax: No Response | 48400 | 64900 | — | — | 66600 |
| Cmax: Complete Response | — | 35700 ± 88.3 | 24800 ± 212 | 80900 ± 31.7 | 35200 ± 65.8 |
| Cmax: Partial Response | — | 17700 | — | 74000 ± 42.1 | 39200 ± 33.1 |
| Ctrough: No Response | 16400 | 1 ± 36800 | — | — | 45000 |
| Ctrough: Complete Response | — | 27000 ± 104 | 17100 ± 151 | 50100 ± 48.6 | 22700 ± 75.3 |
| Ctrough: Partial Response | — | 10800 | — | 24600 ± 132 | 18500 ± 43.6 |
Alternate overall responses were derived using hematological parameters (i.e., hemoglobin, platelet, reticulocyte, and ANC). aORR is defined as the percentage of participants who achieved an alternate complete response (aCR) or an alternate partial response (aPR)
| Percentage of participants | Cohort A: Regimen 1 | Cohort A: Regimen 2 | Cohort B |
|---|---|---|---|
| Week 12 | 90.0 (55.5 to 99.7) | 100 (39.8 to 100.0) | 64.9 (47.5 to 79.8) |
| Week 26 | 90.0 (55.5 to 99.7) | 100 (39.8 to 100.0) | 75.7 (58.8 to 88.2) |
| Week 52 | 60.0 (26.2 to 87.8) | 100 (39.8 to 100.0) | 40.5 (24.8 to 57.9) |
| Week 78 | 50.0 (18.7 to 81.3) | 75.0 (19.4 to 99.4) | 48.6 (31.9 to 65.6) |
PK parameter, AUCtau. AUC tau: Area under the curve calculated to the end of the dosing interval (tau) (mass\*time/volume)
| hr*ng/mL | Cohort A: Regimen 1 | Cohort A: Regimen 2 | Cohort B |
|---|---|---|---|
| Pharmacokinetics (PK) of Eltrombopag at the Starting Dose (AUCtau) | 367000 ± 35.6 | 350000 ± 47.7 | 441000 ± 55.2 |
PK parameter, Cmax Cmax is the observed maximum plasma concentration following administration (mass/volume)
| ng/mL | Cohort A: Regimen 1 | Cohort A: Regimen 2 | Cohort B |
|---|---|---|---|
| PK of Eltrombopag at the Starting Dose (Cmax) | 19700 ± 46.5 | 21000 ± 24.5 | 24000 ± 51.0 |
PK parameter, Ctrough Ctrough is the pre-dose plasma concentration (mass/volume).
| ng/mL | Cohort A: Regimen 1 | Cohort A: Regiment 2 | Cohort B |
|---|---|---|---|
| PK of Eltrombopag at the Starting Dose (Ctrough) | 8760 ± 72.9 | 10900 ± 66.6 | 13200 ± 52.2 |
On-treatment deaths were collected from the first dose of study treatment up to 30 days after last dose of study medication, for a maximum duration of 234 weeks. Post-treatment survival follow-up deaths were collected 31 days after last dose of study medication until date of the last follow-up for the primary analysis, up to 234 weeks.
| Participants | Cohort A: Regiment 1 | Cohort A: Regimen 2 | Cohort B | Total (Cohorts A (Regimen 1 & 2) and B |
|---|---|---|---|---|
| Total deaths | 0 | 1 | 0 | 1 |
| On-treatment deaths | 0 | 0 | 0 | 0 |
| Post-treatment deaths | 0 | 1 | 0 | 1 |
Collected over Adverse Events (AEs) were collected from first dosing (Day 1) until date of the last follow-up, up to 30 weeks. Deaths were collected from randomization to end of study, up to 234 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A - Regimen 1 (On-treatment) | 0/10 (0%) | 4/10 (40%) | 10/10 (100%) |
| Cohort A - Regimen 2 (On-treatment) | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| Total Cohort A (Regiments 1 & 2) (On-treatment) | 0/14 (0%) | 6/14 (42.9%) | 14/14 (100%) |
| Cohort B (On-treatment) | 0/37 (0%) | 23/37 (62.2%) | 37/37 (100%) |
| Total Participants (On-treatment) | 0/51 (0%) | 29/51 (56.9%) | 51/51 (100%) |
| Cohort A - Regimen 1 (Post--treatment) | 0/10 (0%) | — | — |
| Cohort A - Regimen 2 (Post-treatment) | 1/4 (25%) | — | — |
| Total Cohort A (Regimens 1 & 2) (Post-treatment) | 1/14 (7.1%) | — | — |
| Cohort B (Post-treatment) | 0/37 (0%) | — | — |
| All Participants (Cohorts A & B) (Post-treatment) | 1/51 (2%) | — | — |
| Event | Cohort A - Regimen 1 (On-treatment) | Cohort A - Regimen 2 (On-treatment) | Total Cohort A (Regiments 1 & 2) (On-treatment) | Cohort B (On-treatment) | Total Participants (On-treatment) | Cohort A - Regimen 1 (Post--treatment) | Cohort A - Regimen 2 (Post-treatment) | Total Cohort A (Regimens 1 & 2) (Post-treatment) | Cohort B (Post-treatment) | All Participants (Cohorts A & B) (Post-treatment) |
|---|---|---|---|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/10 | 1/4 | 2/14 | 5/37 | 7/51 | — | — | — | — | — |
| StomatitisGastrointestinal disorders | 0/10 | 1/4 | 1/14 | 0/37 | 1/51 | — | — | — | — | — |
| PyrexiaGeneral disorders | 2/10 | 1/4 | 3/14 | 8/37 | 11/51 | — | — | — | — | — |
| Drug-induced liver injuryHepatobiliary disorders | 0/10 | 1/4 | 1/14 | 0/37 | 1/51 | — | — | — | — | — |
| Clostridium difficile infectionInfections and infestations | 0/10 | 1/4 | 1/14 | 0/37 | 1/51 | — | — | — | — | — |
| GastroenteritisInfections and infestations | 0/10 | 1/4 | 1/14 | 1/37 | 2/51 | — | — | — | — | — |
| Staphylococcal infectionInfections and infestations | 0/10 | 1/4 | 1/14 | 1/37 | 2/51 | — | — | — | — | — |
| Acute kidney injuryRenal and urinary disorders | 0/10 | 1/4 | 1/14 | 2/37 | 3/51 | — | — | — | — | — |
| Renal failureRenal and urinary disorders | 0/10 | 1/4 | 1/14 | 0/37 | 1/51 | — | — | — | — | — |
| Septic shockInfections and infestations | 1/10 | 0/4 | 1/14 | 0/37 | 1/51 | — | — | — | — | — |
| Event | Cohort A - Regimen 1 (On-treatment) | Cohort A - Regimen 2 (On-treatment) | Total Cohort A (Regiments 1 & 2) (On-treatment) | Cohort B (On-treatment) | Total Participants (On-treatment) | Cohort A - Regimen 1 (Post--treatment) | Cohort A - Regimen 2 (Post-treatment) | Total Cohort A (Regimens 1 & 2) (Post-treatment) | Cohort B (Post-treatment) | All Participants (Cohorts A & B) (Post-treatment) |
|---|---|---|---|---|---|---|---|---|---|---|
| Gingival hypertrophyGastrointestinal disorders | 0/10 | 3/4 | 3/14 | 4/37 | 7/51 | — | — | — | — | — |
| Blood urea increasedInvestigations | 4/10 | 3/4 | 7/14 | 5/37 | 12/51 | — | — | — | — | — |
| Alanine aminotransferase increasedInvestigations | 7/10 | 1/4 | 8/14 | 16/37 | 24/51 | — | — | — | — | — |
| Aspartate aminotransferase increasedInvestigations | 6/10 | 1/4 | 7/14 | 13/37 | 20/51 | — | — | — | — | — |
| Blood bilirubin increasedInvestigations | 6/10 | 0/4 | 6/14 | 18/37 | 24/51 | — | — | — | — | — |
| Abdominal painGastrointestinal disorders | 1/10 | 2/4 | 3/14 | 13/37 | 16/51 | — | — | — | — | — |
| VomitingGastrointestinal disorders | 1/10 | 2/4 | 3/14 | 18/37 | 21/51 | — | — | — | — | — |
| Blood creatinine increasedInvestigations | 5/10 | 2/4 | 7/14 | 13/37 | 20/51 | — | — | — | — | — |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/10 | 2/4 | 4/14 | 5/37 | 9/51 | — | — | — | — | — |
| ErythemaSkin and subcutaneous tissue disorders | 0/10 | 2/4 | 2/14 | 1/37 | 3/51 | — | — | — | — | — |
Full analysis Set (FAS): FAS comprised all patients to whom study treatment had been assigned.
| Age, Continuous(Years) | Cohort A: Regimen 1 | Cohort A: Regimen 2 | Cohort B | Total |
|---|---|---|---|---|
| Median | 12.0 (4.0 to 17.0) | 10.0 (7.0 to 12.0) | 10.0 (2.0 to 17.0) | 10.0 (2.0 to 17.0) |
| Sex: Female, Male(Participants) | Cohort A: Regimen 1 | Cohort A: Regimen 2 | Cohort B | Total |
|---|---|---|---|---|
| Female | 5 | 1 | 17 | 23 |
| Male | 5 | 3 | 20 | 28 |
| Race/Ethnicity, Customized(Participants) | Cohort A: Regimen 1 | Cohort A: Regimen 2 | Cohort B | Total |
|---|---|---|---|---|
| Caucasian | 4 | 2 | 24 | 30 |
| Black | 2 | 1 | 4 | 7 |
| Asian | 3 | 1 | 9 | 13 |
| Unknown | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided are anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Sep 2017 to primary completion in Apr 2022, 54 months.
Results were first posted in Aug 2026, 4 years 3 months after primary completion. A results delay was requested in Mar 2023.
Of 60 phase 2 interventional studies under Anemia, Aplastic, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 104. This study's 54 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag